Homburger has provided legal counsel to Santhera Pharmaceuticals Holding (SIX: SANN “Santhera”) on its completion of a 10:1 reverse split of its shares. The reverse split, which was approved by shareholders on June 27, 2023, resulted in the
Ironwood Pharmaceuticals (Nasdaq: IRWD), a healthcare company specializing in GI treatments, and VectivBio Holding (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe rare gastrointestinal conditions, have reached an agreement where&
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
Hasten Biopharmaceutic (China) has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Under the agreement, Hasten acquired Roche’s China mainland rights for
Walder Wyss has taken on the role of data protection officer advisor of Swisstransplant. In this capacity, the firm supports Swisstransplant in conducting data protection assessments and implementing measures to ensure compliance under the upcoming
Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its
Niederer Kraft Frey (NKF) advised Ascend Capital Partners on its series A investment in NanoFlex Robotics. Nanoflex is developing a robotic system that allows the precise movement of specially made catheters using electromagnetic controls. The
Homburger advised allosteric modulation company Addex Therapeutics in Plan-les-Ouates, Geneva (SIX: ADXN) in the completion of an equity financing transaction with a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 7,999,998 shares
Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key
Swiss-based travel-tech start-up, Boddy, has entered into a binding merger agreement with TrainAway, a Danish company, to form the largest wellbeing network for travelers worldwide. By affiliating with TrainAway, Boddy will leverage the Danish